Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A dose-finding approach for genomic patterns in phase I trials.

Journal of biopharmaceutical statistics - 2 Sept 2020

Kaneko S, Hirakawa A, Kakurai Y, Hamada C

Abstract excerpt

Precision medicine is an emerging approach for disease treatment and prevention that accounts for individual variability in genes, environment, and lifestyle. Cancer is a genomic disease; therefore, the dose-efficacy and dose-toxicity relationships for molecularly targeted agents in cancer most likely differ, based on the genomic mutation pattern. The individualized optimal dose - the maximal efficacious dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase I as Topic
Share to Computer Simulation
Share to Data Interpretation, Statistical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Models, Statistical

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Research Design

Source

Identifiers

PMID: 32310707
DOI: 10.1080/10543406.2020.1744619

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A dose-finding approach for genomic patterns in phase I trials.PMID 32310707Read ↗

Radiation therapy with phenotypic medicine: towards N-of-1 personalization.Semantic proximity Read ↗

A regularized functional regression model enabling transcriptome-wide dosage-dependent association study of cancer drug responseSemantic proximity Read ↗

GARD is a pan-cancer predictor of radiation therapy benefitSemantic proximity Read ↗

Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.Semantic proximity Read ↗

Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement.Semantic proximity Read ↗

Costing ‘the’ MTD … in 2-DSemantic proximity Read ↗

An Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in OncologySemantic proximity Read ↗

Dose calculation of anticancer drugs.Semantic proximity Read ↗

Interpretable XGBoost-SHAP Model Predicts Nanoparticles Delivery Efficiency Based on Tumor Genomic Mutations and Nanoparticle Properties.Semantic proximity Read ↗

A Bayesian Precision Medicine Framework for Calibrating Individualized Therapeutic Indices in CancerSemantic proximity Read ↗

Identifying optimal biomarker combinations for treatment selection via a robust kernel method.Semantic proximity Read ↗

Sequential designs for individualized dosing in phase I cancer clinical trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.